Abstracts tagged "psoriasis"

Abstract Number: 1096 • 2019 ACR/ARP Annual Meeting
Learning the Relationships Between Psoriatic Arthritis and a Patient’s History of Musculoskeletal Symptoms from Electronic Health Records Using Bayesian Networks
Amelia Green ¹, Theresa Smith ¹ and Neil McHugh¹, ¹University of Bath, Bath, England, United Kingdom
Background/Purpose: Electronic health records (EHRs) from large health care systems provide access to rich and comprehensive patient-specific information from many sources consisting of heterogeneous data…
Abstract Number: 2490 • 2019 ACR/ARP Annual Meeting
The Cutaneous Microbiome of Psoriatic Disease Is Influenced by Disease Susceptibility HLA Alleles but Not Clinical Phenotype
Meital Yerushalmi¹, Osvaldo Espin-Garcia ², Justine (Yang) Ye ³, Remy Pollock ⁴, Sara Rahmati ³, Lihi Eder ⁵, Mark Silverberg ⁶ and Vinod Chandran ⁷, ¹University of Toronto, University Health Network, Toronto, ON, Canada, ²Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴Krembil Research Institute, University Health Network, Toronto, Canada, ⁵Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ⁶Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: Psoriasis is an inflammatory skin disease. Psoriatic arthritis (PsA) is an inflammatory arthritis that affects 30% of psoriasis patients. The heterogeneity of psoriatic disease…
Abstract Number: 1520 • 2019 ACR/ARP Annual Meeting
Long-Term Treatment Patterns of Biologics and Apremilast Among Patients with Moderate-to-Severe Plaque Psoriasis by Psoriatic Arthritis Status
Steven Feldman ¹, Jingchuan Zhang², Diane Martinez ³, Lorena Lopez-Gonzalez ³, Elizabeth Holt Marchlewicz ³, George Shrady ³, Alan Mendelsohn ⁴ and Yang zhao ⁵, ¹Wake Forest Baptist Health, Winston-Salem, NC, ²Sun Pharmaceutical Industries, Princeton, NJ, ³IBM Watson Health, Washington, DC, ⁴Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁵Sun Pharmaceutical Industries, Princeton
Background/Purpose: Long-term real-world treatment patterns of psoriasis patients are not well characterized, especially those with comorbid psoriatic arthritis (PsA). This study examined the treatment patterns…
Abstract Number: 2499 • 2019 ACR/ARP Annual Meeting
Predicting Risk of Developing Psoriatic Arthritis (PsA) in Siblings of Patients with Psoriatic Arthritis
Winifred Badaiki¹, Quan Li ², Tanya Burry ¹, Fiona Landells ¹, Rachel Gehue ¹, Cindy Penney ³, DIanne Codner ¹, Amanda Dohey ¹, Kerri Smith ¹, Fatima Abji ⁴, Dafna Gladman ⁵, Darren O'Rielly ¹, Vinod Chandran ⁶ and Proton Rahman ⁷, ¹Memorial University, St. Johns, Canada, ²Toronto Western Hospital, Toronto, Canada, ³Memorial University, St Johns, Canada, ⁴Memorial University, Toronto, Canada, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁶University Health Network, University of Toronto, Toronto, Canada, ⁷Memorial University, St. Johns, NL, Canada
Background/Purpose: Delay in diagnosis of psoriatic arthritis (PsA) has been shown to contribute to poor radiographic and functional outcome and less successful response to treatment…
Abstract Number: 1523 • 2019 ACR/ARP Annual Meeting
Impact of Body Weight on Efficacy of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis
Alan Menter ¹, Zoe Draelos ², Jayme Heim ³, Jeff Parno ⁴, Alan Mendelsohn⁴, Stephen Rozzo ⁴ and Christopher Griffiths ⁵, ¹Division of Dermatology, Baylor Scott & White, and Texas A&M College of Medicine, Dallas, TX, USA, Dallas, TX, ²Dermatology Consulting Services, High Point, NC, USA, High Point, NC, ³West Michigan Dermatology, Holland, MI, USA, Holland, MI, ⁴Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁵Centre for Dermatology Research, The University of Manchester, Manchester, UK, Manchester, United Kingdom
Background/Purpose: Tildrakizumab (TIL) is a high-affinity, anti–interleukin‐23p19 monoclonal antibody approved for the treatment of moderate-to-severe chronic plaque psoriasis. An inverse efficacy–body weight relationship has been…
Abstract Number: 2502 • 2019 ACR/ARP Annual Meeting
Normalization of Inflammatory Gene Expression and Cellular Markers by Abatacept in the Skin Lesions of Psoriatic Arthritis Patients: A Biopsy Substudy of a Phase III Study
Jennifer Belasco¹, Sandra Garcet ¹, Mustimbo roberts ², Judilyn Fuentes-Duculan ¹, Norma Kunjravia ¹, Inna Cueto ¹, Israel Coats ¹, Xuan Li ¹, Philip Mease ³, Alice Gottlieb ⁴, Oliver FitzGerald ⁵ and James Krueger ¹, ¹The Rockefeller University, New York, NY, ²Bristol-Myers Squibb, Princeton, NJ, ³Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ⁴Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York City, NY, ⁵University College Dublin, Dublin, Ireland
Background/Purpose: Abatacept (ABA), a selective T-cell co-stimulation modulator, has been shown to improve disease activity in patients with psoriatic arthritis (PsA), but its effect on…
Abstract Number: 1526 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in a Phase 3 Study
Wendy Cantrell ¹, Patricia Lee ², Emil Tanghetti ³, Alan Mendelsohn⁴, Jeff Parno ⁴, Stephen Rozzo ⁴ and Wilson Liao ⁵, ¹Department of Dermatology, University of Alabama Birmingham, Birmingham, AL, USA; Dermatology at the Whitaker Clinic, Birmingham, AL, USA, Birmingham, AL, ²Center for Clinical Studies, Webster, TX, USA, Webster, TX, ³Center for Dermatology and Laser Surgery, Sacramento, CA, USA, Sacramento, CA, ⁴Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁵Department of Dermatology, University of California San Francisco, San Francisco, CA, USA, San Francisco, CA
Background/Purpose: We assessed residual plaque psoriasis in patients successfully treated with anti–interleukin-23p19 monoclonal antibody tildrakizumab (TIL) who interrupted treatment, relapsed, and were retreated vs continuously…
Abstract Number: 2504 • 2019 ACR/ARP Annual Meeting
Differential Expression of Human Endogenous Retroviruses in Psoriatic Disease
Remy Pollock¹, Rohan Machhar ¹, Laila Zaman ¹, Dafna Gladman ² and Vinod Chandran ³, ¹Krembil Research Institute, University Health Network, Toronto, Canada, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: Human endogenous retroviruses (HERV) are the stably inherited remnants of ancient retroviruses that infected the ancestral germline. A growing body of research has associated…
Abstract Number: 1527 • 2019 ACR/ARP Annual Meeting
Limited Changes in Hematological Parameters During Tildrakizumab Treatment: Post Hoc Analysis of Data from the Tildrakizumab Psoriasis Clinical Program
Holly Glover ¹, Kristine Kucera ², Alan Mendelsohn³, Jeff Parno ³, Stephen Rozzo ³, Frank Ferritto ⁴ and Renata Block ⁵, ¹Dermatology and Skin Cancer Surgery Center, McKinney, TX, USA, McKinney, TX, ²North Texas Dermatology, Richardson, TX, USA, Richardson, TX, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁴Polley Dermatology, Wilson, NC, USA, Wilson, NC, ⁵Pinski Dermatology & Cosmetic Surgery, Chicago, IL, USA, Chicago, IL
Background/Purpose: Tildrakizumab (TIL) is a high-affinity, anti–interleukin‐23p19 monoclonal antibody with demonstrated efficacy for the treatment of chronic plaque psoriasis in a phase 2b (P05495 [NCT01225731])…
Abstract Number: 2505 • 2019 ACR/ARP Annual Meeting
Can Biologics “Prevent” the Development of Psoriatic Arthritis in Psoriasis Patients? Data from a Large University Hospital Cohort in Argentina
Luciano Fernando Lo Giudice¹, Maria Laura Acosta Felquer ¹, Luis Daniel Mazzuoccolo ², Maria Laura Galimberti ² and Enrique Soriano ³, ¹Hospital Italiano de Buenos Aires, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina
Background/Purpose: As psoriasis (Pso) commonly precedes psoriatic arthritis (PsA), an important unanswered question is whether treatment of Pso might influence the development of PsA in…
Abstract Number: 1610 • 2018 ACR/ARHP Annual Meeting
Incremental Benefits to Quality of Life Associated with Achieving Higher Levels of American College of Rheumatology Response and Skin Clearance in Patients with Psoriatic Arthritis
Josef S. Smolen¹, David Shrom², Chen-Yen Lin², Julie Birt², Georg Schett³ and Alice B Gottlieb⁴, ¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²Eli Lilly and Company, Indianapolis, IN, ³Medical Clinic 3, Friedrich-Alexander University, Erlangen-Nuremberg, Germany, ⁴Department of Dermatology, New York Medical College, New York, NY
Background/Purpose: PsA is a chronic inflammatory disease associated with psoriasis. For optimal quality of life (QoL) improvements, all PsA symptoms should be managed. We examine…
Abstract Number: 1614 • 2018 ACR/ARHP Annual Meeting
Prevalence of Sonographic Enthesitis in Patients with Psoriasis without Arthritis and Its Association Risk Factors of Psoriatic Arthritis
Anwar Albasri¹, Justine Y. Ye², Cheryl F. Rosen³, Vinod Chandran², Dafna D Gladman⁴ and Lihi Eder⁵, ¹Rheumatology, University of Toronto, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Medicine, Toronto Psoriatic Arthritis Research Program, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Enthesitis is one of the hallmarks of psoriatic arthritis (PsA) and may be the initial site of musculoskeletal inflammation. Enthesitis affects up to 50…
Abstract Number: 2447 • 2018 ACR/ARHP Annual Meeting
Liver Enzyme Abnormalities after Tofacitinib Treatment in Patients with Hepatic Steatosis from the Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis Clinical Programs
Enrique R Soriano¹, Hugo Madariaga², Oswaldo Castañeda³, Gustavo Citera⁴, Emilce E Schneeberger⁴, Mario H Cardiel⁵, Thijs Hendrikx⁶, Daniela Graham⁷, Harry Shi⁶ and Dario Ponce de Leon⁸, ¹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Clínica del Sur, Arequipa, Peru, ³Clínica Anglo Americana, Lima, Peru, ⁴Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵Centro de Investigación Clínica de Morelia, Morelia, Mexico, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Lima, Peru
Background/Purpose: Non-alcoholic fatty liver disease, characterized by hepatic steatosis (HS), is a very common form of chronic liver disease in many countries. Limited data are…
Abstract Number: 2567 • 2018 ACR/ARHP Annual Meeting
Clinically Meaningful Improvement in Skin and Nail Psoriasis in Bio-Naïve Active Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Results through Week 24 from a Phase 3 Study
M. Elaine Husni¹, Philip J. Mease², Soumya D Chakravarty³, Shelly Kafka⁴, Diane D. Harrison⁵, Dennis Parenti⁴, Lilianne Kim⁵, Kim Hung Lo⁵, Elizabeth C Hsia⁶ and Arthur Kavanaugh⁷, ¹Cleveland Clinic, Cleveland, OH, ²Swedish Medical Center & U of Wash School of Medicine, Seattle, WA, ³Janssen Scientific Affairs, LLC/Drexel U School of Medicine, Horsham/Phila, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁷UCSD, San Diego, CA
Background/Purpose: GO-VIBRANT was a Phase 3 trial of intravenous (IV) golimumab (GLM) in adult patients (pts) w/active psoriatic arthritis (PsA). To evaluate improvement in skin,…
Abstract Number: 2904 • 2018 ACR/ARHP Annual Meeting
Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients and Healthy Controls
Ralf G. Thiele¹, Yahui Grace Chiu², Nelson Huertas³, Dongge Li⁴, Changyong Feng⁵, Sharon Moorehead⁶, Cristy Bell⁷ and Christopher T. Ritchlin⁸, ¹Division of Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, ³Department of Medicine, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, ⁵Statistics, University of Rochester, Rochester, NY, ⁶Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁷Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁸Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY
Background/Purpose: The events that underlie the transition from psoriasis (Ps) to psoriatic arthritis (PsA) are not well understood, although up to 30% of Ps patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].